Publications by authors named "O Itzhaki"
Pulmonary function tests (PFT) are recommended for hematopoietic cell transplantation (HCT) evaluation. However, their prognostic value in chimeric antigen receptor T-cell (CAR-T) therapy remains unclear. We assessed the predictive significance of PFTs and pulmonary comorbidity classifications, per the Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI), in B-cell lymphoma patients undergoing autologous CD19-CAR-T therapy.
View Article and Find Full Text PDFRelapsed/refractory (r/r) acute myeloid leukemia (AML) is associated with poor prognosis. CD19 is a B-cell marker, is aberrantly expressed in AML, mostly with t(8; 21)(q22; q22.1).
View Article and Find Full Text PDFArticle Synopsis
- * Results showed that while CAR T-cell therapy had similar toxicity levels to other lymphomas, the overall response rates were lower for RT patients (57% response, 47% complete response) compared to those with de novo LBCL.
- * The median overall survival for RT patients was 9.9 months, significantly shorter than the median survival for de novo LBCL (18 months) and transformed indolent non-Hodgkin lymphoma (iN
Article Synopsis
- - CD19 CAR-T cells have shown long-lasting remission in patients with hard-to-treat B-cell cancers, but many eventually relapse, prompting research into ways to enhance their effectiveness.
- - A study found that CAR-T cells leading to complete responses had higher mitochondrial function, suggesting that boosting cellular metabolism could improve their efficacy in treating leukemia.
- - By switching the growth medium from glucose to galactose, researchers increased mitochondrial activity in CAR-T cells, leading to better performance in lab tests and improved leukemia-free survival in mouse models compared to traditional glucose-based methods.